An Open Label, Single Dose, 2-Way Cross-Over Randomized Bioequivalence Study Comparing a Fixed Dose Combination Formulation, Myrin P Forte, (Contains 150 Mg Rifampicin, 75 Mg Isoniazid, 275 Mg Ethambutol and 400 Mg Pyrazinamide Per Tablet) to an Equivalent Dose of Single Drug Reference Preparations of Rifampicin, Isoniazid, Ethambutol and Pyrazinamide Following Oral Administration in Healthy Adults Under Fasting Conditions
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Rifampicin/isoniazid/pyrazinamide/ethambutol (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
- Indications Tuberculosis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 30 Aug 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 30 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.